VIMIAN BTA Stock Overview
Vimian Group AB (publ) engages in the animal health business worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr32.80 |
52 Week High | kr33.70 |
52 Week Low | kr31.60 |
Beta | 1.52 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 2.50% |
Recent News & Updates
Recent updates
Shareholder Returns
VIMIAN BTA | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | 0.3% | -1.0% | 0.4% |
1Y | n/a | -6.2% | 11.4% |
Return vs Industry: Insufficient data to determine how VIMIAN BTA performed against the Swedish Medical Equipment industry.
Return vs Market: Insufficient data to determine how VIMIAN BTA performed against the Swedish Market.
Price Volatility
VIMIAN BTA volatility | |
---|---|
VIMIAN BTA Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.3% |
Market Average Movement | 6.3% |
10% most volatile stocks in SE Market | 13.5% |
10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: VIMIAN BTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VIMIAN BTA's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 1,000 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
VIMIAN BTA fundamental statistics | |
---|---|
Market cap | kr17.00b |
Earnings (TTM) | kr113.35m |
Revenue (TTM) | kr3.82b |
150.0x
P/E Ratio4.5x
P/S RatioIs VIMIAN BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIMIAN BTA income statement (TTM) | |
---|---|
Revenue | €331.73m |
Cost of Revenue | €102.30m |
Gross Profit | €229.43m |
Other Expenses | €219.59m |
Earnings | €9.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 0.019 |
Gross Margin | 69.16% |
Net Profit Margin | 2.97% |
Debt/Equity Ratio | 57.4% |
How did VIMIAN BTA perform over the long term?
See historical performance and comparison